A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.
about
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel TherapiesContribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosisGlobal transcriptional profiling of longitudinal clinical isolates of Mycobacterium tuberculosis exhibiting rapid accumulation of drug resistancePlasma drug activity in patients on treatment for multidrug-resistant tuberculosisGenomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosisRedefining multidrug-resistant tuberculosis based on clinical response to combination therapy.Isoniazid inhibits the heme-based reactivity of Mycobacterium tuberculosis truncated hemoglobin NSubtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.Gelation Behavior of 5-Chloro-8-hydroxyquinoline, an Antituberculosis Agent in Aqueous Alcohol Solutions.The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistanceThe heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.Prediction of Drug Penetration in Tuberculosis LesionsRibosomal mutations promote the evolution of antibiotic resistance in a multidrug environmentInhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs.Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis.The challenges of pharmacokinetic variability of first-line anti-TB drugs.Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish.Oxidative stress and TB outcomes in patients with diabetes mellitus?Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.The role of metabolomics in tuberculosis treatment research.embB306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosis.Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis.Insights into the processes that drive the evolution of drug resistance in Mycobacterium tuberculosisFatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis
P2860
Q26771848-B2B83BAD-5BE7-4E83-8677-AD6FAD16F811Q26778117-9E70D93B-3966-4663-8D13-883E62C18081Q28482174-DFB03978-97D5-4A50-B5C3-22720031FB56Q28485244-762D30E3-E37B-4759-B7E6-FE1AB83A15F1Q30411475-C491731D-E6DE-4A56-979F-695C103323EDQ33595994-1EDF9473-D96A-4C0D-9A0D-FFDC42ABC7C2Q33926262-B25AFF28-C21B-41AD-B89A-1954448C8FFEQ34298988-8D826990-0E65-4C7F-9E13-F59358D83D8CQ34924586-088FE498-E07E-4189-BB31-66299C72D35DQ35167178-07D05C62-0E47-459A-A1F0-92E1E32F81BEQ35169089-78B2880E-A598-4BAF-8185-7E9574D6F2CBQ35974411-1C92A058-34B2-4153-B4D5-44BE9C3CCF63Q36172383-938C35BA-9CFD-4871-BE05-1AC5FF48EA06Q36675409-E29056C3-128F-428D-B994-3ED01DDAFD14Q37119998-B9CF4030-E3C0-4779-9651-1E59190CA4ADQ37265786-AFFF4336-8351-40B2-AC98-8F31415C0BE1Q37656663-6337E249-DACA-415B-8B96-F51CCE8FA274Q38056146-7EBAD1C0-F0A8-493F-B5AC-D22601762AECQ38872081-BF22B307-F503-4215-B755-865A61EEB524Q38977166-E685206A-EB76-4BA0-9F0A-86226513C223Q40184248-1A76ACE1-BC8E-4888-A31C-569414C974FBQ40316822-5B448A8A-304E-48DD-94BD-CE8F300F081FQ40330811-0291751E-6136-4880-8922-851FFA99EAEAQ41082086-E04F195C-150F-454C-A579-4BA30C1667B4Q46462804-853DDAEA-89FD-4C9E-8FF7-C20EAB44C1E9Q46639370-E5A7F0EA-0262-4DB6-A72B-C7C66E7460A9Q50313165-DA8D61A3-0919-4FF3-AC1D-2FB241DB0D57Q56828266-6BE2076C-57E8-44FC-A2CA-2AF721BEE8C2Q58033431-6F6CC862-BA6A-4DAB-9E5A-FDE0811D506A
P2860
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A new evolutionary and pharmac ...... tiple anti-tuberculosis drugs.
@ast
A new evolutionary and pharmac ...... tiple anti-tuberculosis drugs.
@en
type
label
A new evolutionary and pharmac ...... tiple anti-tuberculosis drugs.
@ast
A new evolutionary and pharmac ...... tiple anti-tuberculosis drugs.
@en
prefLabel
A new evolutionary and pharmac ...... tiple anti-tuberculosis drugs.
@ast
A new evolutionary and pharmac ...... tiple anti-tuberculosis drugs.
@en
P2860
P1476
A new evolutionary and pharmac ...... tiple anti-tuberculosis drugs.
@en
P2093
Jotam G Pasipanodya
P2860
P304
P356
10.1016/J.COPH.2011.07.001
P577
2011-07-30T00:00:00Z